Asthma
Conditions
Keywords
Persistent, Eosinophilic, Asthma
Brief summary
The primary objective of the study is to evaluate the efficacy of TEV-53275 administered subcutaneously (sc) in adult participants with persistent asthma and an eosinophilic phenotype compared to placebo. A secondary objective is to evaluate the efficacy of TEV-53275 compared to placebo assessed by lung function, asthma symptoms, rescue medication use, and quality of life measures. Another secondary objective is to evaluate the safety and tolerability of TEV-53275 administered sc in adult participants with persistent asthma and an eosinophilic phenotype compared with placebo, and lastly, to evaluate the immunogenicity of TEV-53275 administered sc in adult participants with persistent asthma and an eosinophilic phenotype.
Detailed description
The planned study duration is approximately 16 months. The total duration of study participation is approximately 34 weeks including up to a 2-week screening period, a 2-week run-in period, a 16-week treatment period, and a follow-up visit 14 weeks after the final treatment visit.
Interventions
DRUGTEV-53275 Dose A
subcutaneous (sc) injection
DRUGTEV-53275 Dose B
subcutaneous (sc) injection
DRUGPlacebo
Matching subcutaneous (sc) placebo injection
Sponsors
Teva Branded Pharmaceutical Products R&D, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* The participant is an adult female or male ≥18 years of age. Note: Age requirements are as specified or allowed by local regulations. * The participant has a diagnosis of asthma for at least 6 months and has been stable without exacerbation or change in medications for at least 1 month.. * Current Asthma Therapy: The participant has been maintained for at least 1 month on stable doses of: * medium or high dose inhaled corticosteroids (ICS)±another controller. * any fixed dose combination ICS (low, medium, or high) with long-acting beta agonist (LABA)±another controller. * Women of non-childbearing potential, or congenitally sterile, or 1-year postmenopausal. Women of childbearing potential must have a negative β-human chorionic gonadotropin (β-HCG) test result and practice a highly effective method of birth control prior to investigational medicinal product (IMP) administration and 30 weeks after the dose of IMP. * The participant, as judged by the investigator, is able to continue their current asthma maintenance medications throughout the study. NOTE- Additional criteria apply, please contact the investigator for more information.
Exclusion criteria
* Life threatening asthma, defined as a history of asthma episode(s) requiring intubation and/or associated hypercapnea, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s). * The participant has a suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear that has not resolved at least 2 weeks before the screening period. Note: Participants who develop an upper respiratory infection/lower respiratory infection (URI/LRI) during the run-in period may rescreen 2 weeks after symptoms resolve and undergo coronavirus disease 2019 (COVID-19) testing. * Participants with a confirmed infection with COVID-19 within 3 months prior to the screening visit. * The participant has an eosinophilic condition including hypereosinophilic syndrome, eosinophilic pneumonia, eosinophilic granulomatosis with polyangiitis (EGPA \[Churg Strauss syndrome\]), or allergic bronchopulmonary aspergillosis. * The participant has an active helminthic or parasitic infection currently or within the last 6 months. * The participant has a history of malignancy other than fully resected basal cell carcinoma of the skin. * The participant has any clinically significant, uncontrolled medical or psychiatric condition (treated or untreated) that would interfere with the study schedule or procedures, interpretation of efficacy results, or compromise the participant's safety. * The participant has known history of, or a positive test result for, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies (Ab), or human immunodeficiency virus (HIV) Types 1 or 2 Ab (according to 4th generation serology testing). * The participant is a pregnant or lactating woman, or plans to become pregnant during the study. * The participant has previously participated in a study with TEV-53275. * The participant has participated in another study of an IMP (or a medical device) within the previous 30 days or is currently participating in another study of an IMP (or a medical device). * The participant has been treated with a monoclonal antibody used to treat asthma or other inflammatory conditions within the washout period (5 half-lives), has demonstrated hypersensitivity or anaphylaxis to a monoclonal antibody (Appendix G),or is currently using or has used a systemic immunosuppressive medication within the last 6 months. NOTE: Prior depemokimab exposure is prohibited without exception. * The participant has a history of chronic alcohol or drug abuse within the previous 2 years. * The participant currently smokes or has a smoking history of 10 pack years or more (a pack year is defined as smoking 1 pack of cigarettes \[20 cigarettes\]/day for 1 year), OR the participant used tobacco products within the past year (eg, cigarettes, cigars, chewing tobacco, or pipe tobacco), OR the participant has smoked marijuana within 1 month, OR the participant has a history of vaping tobacco, marijuana, or any other substance within 24 months. * Vulnerable participants (eg, people kept in detention). NOTE- Additional criteria apply, please contact the investigator for more information
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Clinic-based Standardized Baseline-adjusted Morning Trough (Pre-bronchodilator) FEV1 at Week 12 | Baseline, Week 12 | FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Least square (LS) mean and standard error (SE) were calculated using a mixed model for repeated measures (MMRM). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in the Weekly Average of Daily Morning Trough (Pre-Rescue Bronchodilator) FEV1 Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Baseline, up to Week 12, up to Week 16 | FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by a handheld device. The post-baseline analysis window for over 12 weeks was from the first day of study drug up to Day 84. The post-baseline analysis window for over 16 weeks was from the first day of study drug up to Day 112. The daily average of the efficacy data with each weekly analysis window was calculated based on non-missing e-diary as follow: Summation of FEV1 during an analysis window/Number of days with nonmissing data in the analysis window. LS mean and SE was calculated using an MMRM. |
| Change From Baseline in Weekly Average of Rescue Medication Use Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Baseline, up to Week 12, up to Week 16 | The number of times asthma rescue medication (number of inhalations/puffs) was used was assessed (for example, by reviewing the electronic diary or if required due to missing data in the diary, by site tracking of the inhalation counter on the inhaler). Rescue medication included albuterol sulfate inhalation powder (albuterol eMDPI) or equivalent albuterol/salbutamol. The post-baseline analysis window for over 12 weeks was from the first day of study drug up to Day 84. The post-baseline analysis window for over 16 weeks was from the first day of study drug up to Day 112. The daily average of the efficacy data with each weekly analysis window was calculated based on non-missing e-diary as follow: Summation of rescue medication uses during an analysis window/Number of days with nonmissing data in the analysis window. LS mean and SE were calculated using Wilcoxon rank-sum test stratified on randomization stratification factors. |
| Change From Baseline in Weekly Percentage of Asthma Control Days (No Symptoms and No Rescue Medication Use) Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Baseline, up to Week 12, up to Week 16 | An asthma control day was defined as a day on which the participant used 0 puffs of inhaled short-acting β-adrenergic agonist (SABA), had no night-time awakenings, and experienced no asthma exacerbations. The post-baseline analysis window for over 12 weeks was from the first day of study drug up to Day 84. The post-baseline analysis window for over 16 weeks was from the first day of study drug up to Day 112. Percentage of asthma control days in each analysis window was calculated as follow: Summation of asthma control days in an analysis window/Number of days with nonmissing data in the analysis window \* 100. |
| Change From Baseline in Clinic-based Standardized Baseline-adjusted Morning Trough (Pre-bronchodilator) FEV1 at Week 16 | Baseline, Week 16 | FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. LS mean and SE were calculated using an MMRM. |
| Number of Participants Who Achieved Clinic-based FEV1 ≥80% Predicted at Weeks 12 and 16 | Weeks 12 and 16 | The percent of predicted FEV1 (the volume of air exhaled in the first second of a forced expiration) was measured by handheld device. |
| Number of Participants Who Achieved Forced Expiratory Flow at 25% to 75% of Forced Expiratory Volume (FVC) (FEF25-75) ≥70% Predicted at Weeks 12 and 16 | Weeks 12 and 16 | The FVC is the volume of air that can be forcibly blown out after full inspiration. FVC results in this study were presented as the forced expiratory flow at 25% to 75% of FVC. |
| Change From Baseline in FEF25-75 Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Baseline, up to Week 12, up to Week 16 | The FVC is the volume of air that can be forcibly blown out after full inspiration. FVC results in this study were presented as the forced expiratory flow at 25% to 75% of FVC. The post-baseline analysis window for over 12 weeks was from the first day of study drug up to Day 84. The post-baseline analysis window for over 16 weeks was from the first day of study drug up to Day 112. The daily average of the efficacy data with each weekly analysis window was calculated based on non-missing e-diary as follow: Summation of FEF25-75 during an analysis window/Number of days with nonmissing data in the analysis window. LS mean and SE were calculated using an MMRM. |
| Time to First Clinical Asthma Exacerbation (CAE) | Baseline up to Week 16 | The time (days) to the first CAE was the interval from the randomization to the occurrence of the first CAE. A CAE was defined as worsening asthma requiring treatment with a systemic corticosteroid for at least 3 days, emergency room visit resulting in systemic corticosteroid treatment, or hospitalization due to asthma. Worsening asthma included new or increased symptoms or signs that either worried the participant or were related to an asthma-specific alert (if available through the electronic diary/handheld spirometer) and required the addition of maintenance medications (other than systemic corticosteroids) to control the participant's asthma symptoms based on the investigator's judgment. |
| Change From Baseline in Asthma Control Questionnaire (ACQ-6) Score at Weeks 12 and 16 | Baseline, Week 12, Week 16 | The ACQ-6 is a validated 6-item asthma assessment tool that has been widely used. Six questions are self-assessments (completed by the participant), 5 questions assessing asthma symptoms: night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and 1 question for short-acting bronchodilator use. Each item on the ACQ has a possible score ranging from 0 (no impairment) to 6 (maximum impairment), and the total score is the mean of all responses. The total score ranging from 0 (totally controlled) to 6 (severely uncontrolled) with higher scores indicating maximum impairment. |
| Change From Baseline in Asthma Control Test (ACT) Score at Weeks 12 and 16 | Baseline, Week 12, Week 16 | The Asthma Control Test (ACT) is a participant self-administered tool for identifying those with poorly controlled asthma comprising 5 items, with 4-week recall (on symptoms and daily functioning). It assesses the frequency of shortness of breath and general asthma symptoms, the use of rescue medications, the effect of asthma on daily functioning, and the overall self-assessment of asthma control measured on a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled). Total scores range from 5 (poor control of asthma) to 25 (complete control of asthma), with higher scores reflecting greater asthma control. An ACT score \>19 indicates well-controlled asthma. |
| Change From Baseline in Standardized Asthma Quality of Life Questionnaire (AQLQ[S]) Overall Score at Weeks 12 and 16 | Baseline, Week 12, Week 16 | The AQLQ\[S\] (participants ≥18 years of age version) was self-administered by participants. The questionnaire is a tool to measure the impact of asthma on a participant's quality of life (physical, emotional, social, and occupational). The aim of the questionnaire is to evaluate the problems that were most troublesome to participants in their day to day lives. The questionnaire contains 32 items with a 2-week recall period and used a 7-point Likert scale (7=not impaired at all to 1=severely impaired). The overall AQLQ score was the mean of the responses to each of the 32 questions and ranged from 1 (severely impaired) to 7 (not impaired at all) with higher scores indicating better quality of life. |
| Number of Participants With Well-controlled Asthma Status (Yes Versus No) at Weeks 12 and 16 | Weeks 12 and 16 | The weekly asthma control status (Yes or No) is the derived asthma control composite score based on the following criteria: 1\. Two or more of the following criteria were fulfilled: * ≤2 days with a daily asthma symptom score \>1; - ≤2 days of albuterol/salbutamol used as rescue medication up to a maximum of 4 occasions per week (multiple occasions per day are counted as separate occasions); - morning FEV1 ≥80% predicted for each day (by handheld device) and 2. Both of the following criteria were fulfilled: * no night-time awakenings due to asthma; - no use of asthma maintenance medications. The asthma control status in each weekly analysis window was Yes if the conditions 1 and 2 above were met, No otherwise. |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Baseline up to Week 30 | An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse events (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAEs were defined as AEs that occurred after the first dose of study drug was administered through the end of the study. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. |
| Number of Participants Who Received at Least 1 Concomitant Asthma Medication | Baseline up to Week 30 | Concomitant asthma medications included Antihistamines for systemic use (Cetirizine); Corticosteroids for systemic use (Prednisone, Methylprednisolone); and Drugs for obstructive airway diseases (Salbutamol, Fluticasone etc.). |
| Number of Participants Developing Antidrug Antibodies (ADAs) Throughout the Study | Baseline up to Week 30 | A participant was classified as having a treatment-emergent ADA response if either of the following were true: - The participant had a positive sample at any of the postdose time points, but not at the predose (baseline) time point; - The participant had a positive sample at predose (baseline) and 1 or more postdose time points, but the titer of a postdose sample(s) was increased by at least 4-fold when comparing it to that of the predose sample. |
| Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Serum Chemistry Value | Baseline up to Week 30 | Potentially clinically significant serum chemistry abnormalities included: Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase, Gamma-glutamyl transpeptidase (GGT), Lactate dehydrogenase (LDH), and Creatinine phosphokinase each ≥3 \* upper limit of normal (ULN); Blood urea nitrogen ≥10.71 millimoles (mmol)/liter (L); Creatinine ≥177 micromoles (μmol)/L; and Bilirubin (total) ≥34.2 μmol /L. |
| Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Hematology Value | Baseline up to Week 30 | Potentially clinically significant hematological abnormalities included: White blood cells (WBCs) count ≤3.0 \*10\^9 cells/L or ≥20 \* 10\^9 cells/L; Hemoglobin ≤95 grams (g)/L in females and ≤115 g/L in males; Hematocrit \<0.32 L/L in females and \<0.37 L/L in males; Platelet count ≤75 \* 10\^9 cells/L or ≥700 \* 10\^9 cells/L; and Absolute neutrophil count (ANC) ≤1 \* 10\^9 cells/L. |
| Number of Participants With at Least 1 Potentially Clinically Significant Urinalysis Abnormalities | Baseline up to Week 30 | Potentially clinically significant urinalysis abnormalities included: ≥2 unit increase from baseline in urine hemoglobin, ketones, glucose, and total protein. |
| Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Vital Signs Value | Baseline up to Week 30 | Potentially clinically significant vital signs abnormalities included: Systolic blood pressure (BP): ≤90 millimeters of mercury (mmHg) and decrease from baseline of 20 mm Hg or ≥180 mm Hg and increase from baseline of ≥20 mm Hg; Diastolic BP: ≥105 mmHg and increase from baseline of ≥15 mmHg or ≤50 mmHg and decrease from baseline of ≥15 mmHg; Pulse ≥120 beats per minute (bpm) and increase from baseline of ≥15 bpm or ≤50 bpm and decrease from baseline of ≥15 bpm; Temperature ≥38.3 degrees celsius (ºC) and change from baseline of ≥1.1 ºC; Respiratory rate \>24 breaths/min and increase from baseline of ≥10 breaths/min. |
| Number of Participants With Potentially Clinically Significant Abnormal Electrocardiogram Values | Baseline up to Week 30 | Potentially clinically significant electrocardiogram abnormalities including any one of the following values: QTc interval \>450 milliseconds (msec) and QTc interval increases from baseline \>30 msec, QTc interval \>450 msec and QTc interval increases from baseline \>60 msec, QTc interval \>500 msec and QTc interval increases from baseline \>30 msec, QTc interval \>500 msec and QTc interval increases from baseline \>60 msec; QRS duration \>110 msec and a 25% increase from baseline; and PR interval \>200 msec and a 25% increase from baseline. |
| Number of Participants With Injection Site Reactions | Baseline up to Week 30 | Injection site reactions included erythema, ecchymosis, induration, tenderness, warmth, and swelling. Number of participants with erythema, ecchymosis, and induration were reported in following categories: Absent; 5 millimeters (mm) to ≤50 mm (mild); \>50 mm to ≤100 mm (moderate); and \>100 mm (severe). Number of participants with tenderness, warmth, and swelling were reported in following categories: Absent; mild; moderate; and severe. |
| Number of Participants Who Did Not Complete the Study Due to AEs | Baseline up to Week 30 | An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Number of participants who did not complete the study due to AEs were reported. |
| Number of Participants Who Achieved FEV1:FVC Ratio ≥0.80 at Weeks 12 and 16 | Weeks 12 and 16 | FEV1 was the volume of air exhaled in the first second of a forced expiration. FVC is the volume of air that can be forcibly blown out after full inspiration. |
Countries
Canada, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Placebo Participants received placebo matched to TEV-53275 SC at baseline (Day 0). | 32 |
| TEV-53275 Dose A Participants received TEV-53275 Dose A SC at baseline (Day 0). | 33 |
| TEV-53275 Dose B Participants received TEV-53275 Dose B SC at baseline (Day 0). | 32 |
| Total | 97 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 0 | 0 | 2 |
| Overall Study | Other than specified | 21 | 20 | 20 |
| Overall Study | Withdrawal by Subject | 0 | 1 | 0 |
Baseline characteristics
| Characteristic | Placebo | TEV-53275 Dose A | TEV-53275 Dose B | Total |
|---|---|---|---|---|
| Age, Continuous | 51.3 years STANDARD_DEVIATION 12.94 | 51.2 years STANDARD_DEVIATION 13.79 | 53.2 years STANDARD_DEVIATION 15.05 | 51.9 years STANDARD_DEVIATION 13.83 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 4 Participants | 9 Participants | 5 Participants | 18 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 28 Participants | 24 Participants | 27 Participants | 79 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Forced Expiratory Volume in 1 Second (FEV1) | 1.938 liters STANDARD_DEVIATION 0.5931 | 1.957 liters STANDARD_DEVIATION 0.6961 | 2.064 liters STANDARD_DEVIATION 0.7411 | 1.986 liters STANDARD_DEVIATION 0.6757 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 2 Participants | 1 Participants | 4 Participants |
| Race (NIH/OMB) Black or African American | 6 Participants | 6 Participants | 1 Participants | 13 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) White | 25 Participants | 25 Participants | 29 Participants | 79 Participants |
| Sex: Female, Male Female | 23 Participants | 18 Participants | 19 Participants | 60 Participants |
| Sex: Female, Male Male | 9 Participants | 15 Participants | 13 Participants | 37 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 31 | 0 / 34 | 0 / 31 |
| other Total, other adverse events | 5 / 31 | 10 / 34 | 1 / 31 |
| serious Total, serious adverse events | 0 / 31 | 2 / 34 | 1 / 31 |
Outcome results
Primary
Change From Baseline in Clinic-based Standardized Baseline-adjusted Morning Trough (Pre-bronchodilator) FEV1 at Week 12
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. Least square (LS) mean and standard error (SE) were calculated using a mixed model for repeated measures (MMRM).
Time frame: Baseline, Week 12
Population: The mITT analysis set included all randomized participants who received at least a partial dose of study drug. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Clinic-based Standardized Baseline-adjusted Morning Trough (Pre-bronchodilator) FEV1 at Week 12 | 0.152 liters | Standard Error 0.0746 |
| TEV-53275 Dose A | Change From Baseline in Clinic-based Standardized Baseline-adjusted Morning Trough (Pre-bronchodilator) FEV1 at Week 12 | 0.125 liters | Standard Error 0.0724 |
| TEV-53275 Dose B | Change From Baseline in Clinic-based Standardized Baseline-adjusted Morning Trough (Pre-bronchodilator) FEV1 at Week 12 | 0.140 liters | Standard Error 0.0718 |
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline FEV1 as a covariate.p-value: 0.791495% CI: [-0.2276, 0.174]Mixed Models Analysis
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline FEV1 as a covariate.p-value: 0.911595% CI: [-0.2126, 0.19]Mixed Models Analysis
Secondary
Change From Baseline in Asthma Control Questionnaire (ACQ-6) Score at Weeks 12 and 16
The ACQ-6 is a validated 6-item asthma assessment tool that has been widely used. Six questions are self-assessments (completed by the participant), 5 questions assessing asthma symptoms: night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and 1 question for short-acting bronchodilator use. Each item on the ACQ has a possible score ranging from 0 (no impairment) to 6 (maximum impairment), and the total score is the mean of all responses. The total score ranging from 0 (totally controlled) to 6 (severely uncontrolled) with higher scores indicating maximum impairment.
Time frame: Baseline, Week 12, Week 16
Population: The mITT analysis set included all randomized participants who received at least a partial dose of study drug. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed = participants evaluable at specified timepoint.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Asthma Control Questionnaire (ACQ-6) Score at Weeks 12 and 16 | Change in ACQ-6 score at Week 12 | -1.1 units on a scale | Standard Error 0.16 |
| Placebo | Change From Baseline in Asthma Control Questionnaire (ACQ-6) Score at Weeks 12 and 16 | Change in ACQ-6 score at Week 16 | -1.0 units on a scale | Standard Error 0.16 |
| TEV-53275 Dose A | Change From Baseline in Asthma Control Questionnaire (ACQ-6) Score at Weeks 12 and 16 | Change in ACQ-6 score at Week 12 | -1.1 units on a scale | Standard Error 0.16 |
| TEV-53275 Dose A | Change From Baseline in Asthma Control Questionnaire (ACQ-6) Score at Weeks 12 and 16 | Change in ACQ-6 score at Week 16 | -1.1 units on a scale | Standard Error 0.16 |
| TEV-53275 Dose B | Change From Baseline in Asthma Control Questionnaire (ACQ-6) Score at Weeks 12 and 16 | Change in ACQ-6 score at Week 12 | -1.0 units on a scale | Standard Error 0.15 |
| TEV-53275 Dose B | Change From Baseline in Asthma Control Questionnaire (ACQ-6) Score at Weeks 12 and 16 | Change in ACQ-6 score at Week 16 | -1.0 units on a scale | Standard Error 0.16 |
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline ACQ-6 as a covariate.p-value: 0.982995% CI: [-0.43, 0.42]Mixed Models Analysis
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline ACQ-6 as a covariate.p-value: 0.630295% CI: [-0.32, 0.52]Mixed Models Analysis
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline ACQ-6 as a covariate.p-value: 0.670795% CI: [-0.54, 0.35]Mixed Models Analysis
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline ACQ-6 as a covariate.p-value: 0.99495% CI: [-0.44, 0.43]Mixed Models Analysis
Secondary
Change From Baseline in Asthma Control Test (ACT) Score at Weeks 12 and 16
The Asthma Control Test (ACT) is a participant self-administered tool for identifying those with poorly controlled asthma comprising 5 items, with 4-week recall (on symptoms and daily functioning). It assesses the frequency of shortness of breath and general asthma symptoms, the use of rescue medications, the effect of asthma on daily functioning, and the overall self-assessment of asthma control measured on a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled). Total scores range from 5 (poor control of asthma) to 25 (complete control of asthma), with higher scores reflecting greater asthma control. An ACT score \>19 indicates well-controlled asthma.
Time frame: Baseline, Week 12, Week 16
Population: The mITT analysis set included all randomized participants who received at least a partial dose of study drug. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed = participants evaluable at specified timepoint.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Asthma Control Test (ACT) Score at Weeks 12 and 16 | Change at Week 12 | 4.8 units on a scale | Standard Error 0.75 |
| Placebo | Change From Baseline in Asthma Control Test (ACT) Score at Weeks 12 and 16 | Change at Week 16 | 4.6 units on a scale | Standard Error 0.72 |
| TEV-53275 Dose A | Change From Baseline in Asthma Control Test (ACT) Score at Weeks 12 and 16 | Change at Week 12 | 4.1 units on a scale | Standard Error 0.73 |
| TEV-53275 Dose A | Change From Baseline in Asthma Control Test (ACT) Score at Weeks 12 and 16 | Change at Week 16 | 4.0 units on a scale | Standard Error 0.71 |
| TEV-53275 Dose B | Change From Baseline in Asthma Control Test (ACT) Score at Weeks 12 and 16 | Change at Week 12 | 3.6 units on a scale | Standard Error 0.7 |
| TEV-53275 Dose B | Change From Baseline in Asthma Control Test (ACT) Score at Weeks 12 and 16 | Change at Week 16 | 3.7 units on a scale | Standard Error 0.68 |
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline ACT as a covariate.p-value: 0.468395% CI: [-2.71, 1.26]Mixed Models Analysis
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline ACT as a covariate.p-value: 0.223995% CI: [-3.16, 0.75]Mixed Models Analysis
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline ACT as a covariate.p-value: 0.538995% CI: [-2.51, 1.32]Mixed Models Analysis
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline ACT as a covariate.p-value: 0.356495% CI: [-2.75, 1]Mixed Models Analysis
Secondary
Change From Baseline in Clinic-based Standardized Baseline-adjusted Morning Trough (Pre-bronchodilator) FEV1 at Week 16
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by spirometer. LS mean and SE were calculated using an MMRM.
Time frame: Baseline, Week 16
Population: The mITT analysis set included all randomized participants who received at least a partial dose of study drug. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Clinic-based Standardized Baseline-adjusted Morning Trough (Pre-bronchodilator) FEV1 at Week 16 | 0.175 liters | Standard Error 0.0787 |
| TEV-53275 Dose A | Change From Baseline in Clinic-based Standardized Baseline-adjusted Morning Trough (Pre-bronchodilator) FEV1 at Week 16 | 0.092 liters | Standard Error 0.0771 |
| TEV-53275 Dose B | Change From Baseline in Clinic-based Standardized Baseline-adjusted Morning Trough (Pre-bronchodilator) FEV1 at Week 16 | 0.086 liters | Standard Error 0.0754 |
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline FEV1 as a covariate.p-value: 0.439495% CI: [-0.2971, 0.1301]Mixed Models Analysis
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline FEV1 as a covariate.p-value: 0.405195% CI: [-0.302, 0.1231]Mixed Models Analysis
Secondary
Change From Baseline in FEF25-75 Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16
The FVC is the volume of air that can be forcibly blown out after full inspiration. FVC results in this study were presented as the forced expiratory flow at 25% to 75% of FVC. The post-baseline analysis window for over 12 weeks was from the first day of study drug up to Day 84. The post-baseline analysis window for over 16 weeks was from the first day of study drug up to Day 112. The daily average of the efficacy data with each weekly analysis window was calculated based on non-missing e-diary as follow: Summation of FEF25-75 during an analysis window/Number of days with nonmissing data in the analysis window. LS mean and SE were calculated using an MMRM.
Time frame: Baseline, up to Week 12, up to Week 16
Population: The mITT analysis set included all randomized participants who received at least a partial dose of study drug.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in FEF25-75 Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change in FEF25-75 over 12 weeks | 0.086 liters/second | Standard Error 0.0742 |
| Placebo | Change From Baseline in FEF25-75 Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change in FEF25-75 over 16 weeks | 0.098 liters/second | Standard Error 0.0772 |
| TEV-53275 Dose A | Change From Baseline in FEF25-75 Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change in FEF25-75 over 12 weeks | 0.179 liters/second | Standard Error 0.0734 |
| TEV-53275 Dose A | Change From Baseline in FEF25-75 Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change in FEF25-75 over 16 weeks | 0.185 liters/second | Standard Error 0.0763 |
| TEV-53275 Dose B | Change From Baseline in FEF25-75 Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change in FEF25-75 over 12 weeks | 0.119 liters/second | Standard Error 0.0721 |
| TEV-53275 Dose B | Change From Baseline in FEF25-75 Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change in FEF25-75 over 16 weeks | 0.108 liters/second | Standard Error 0.0749 |
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline FEF25-75 as a covariate.p-value: 0.348595% CI: [-0.1031, 0.2893]Mixed Models Analysis
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline FEF25-75 as a covariate.p-value: 0.743295% CI: [-0.1644, 0.2296]Mixed Models Analysis
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline FEF25-75 as a covariate.p-value: 0.401495% CI: [-0.118, 0.292]Mixed Models Analysis
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline FEF25-75 as a covariate.p-value: 0.925995% CI: [-0.196, 0.2153]Mixed Models Analysis
Secondary
Change From Baseline in Standardized Asthma Quality of Life Questionnaire (AQLQ[S]) Overall Score at Weeks 12 and 16
The AQLQ\[S\] (participants ≥18 years of age version) was self-administered by participants. The questionnaire is a tool to measure the impact of asthma on a participant's quality of life (physical, emotional, social, and occupational). The aim of the questionnaire is to evaluate the problems that were most troublesome to participants in their day to day lives. The questionnaire contains 32 items with a 2-week recall period and used a 7-point Likert scale (7=not impaired at all to 1=severely impaired). The overall AQLQ score was the mean of the responses to each of the 32 questions and ranged from 1 (severely impaired) to 7 (not impaired at all) with higher scores indicating better quality of life.
Time frame: Baseline, Week 12, Week 16
Population: The mITT analysis set included all randomized participants who received at least a partial dose of study drug. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed = participants evaluable at specified timepoint.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Standardized Asthma Quality of Life Questionnaire (AQLQ[S]) Overall Score at Weeks 12 and 16 | Change at Week 12 | 1.0 units on a scale | Standard Error 0.17 |
| Placebo | Change From Baseline in Standardized Asthma Quality of Life Questionnaire (AQLQ[S]) Overall Score at Weeks 12 and 16 | Change at Week 16 | 0.9 units on a scale | Standard Error 0.18 |
| TEV-53275 Dose A | Change From Baseline in Standardized Asthma Quality of Life Questionnaire (AQLQ[S]) Overall Score at Weeks 12 and 16 | Change at Week 12 | 0.8 units on a scale | Standard Error 0.17 |
| TEV-53275 Dose A | Change From Baseline in Standardized Asthma Quality of Life Questionnaire (AQLQ[S]) Overall Score at Weeks 12 and 16 | Change at Week 16 | 0.7 units on a scale | Standard Error 0.18 |
| TEV-53275 Dose B | Change From Baseline in Standardized Asthma Quality of Life Questionnaire (AQLQ[S]) Overall Score at Weeks 12 and 16 | Change at Week 12 | 0.8 units on a scale | Standard Error 0.16 |
| TEV-53275 Dose B | Change From Baseline in Standardized Asthma Quality of Life Questionnaire (AQLQ[S]) Overall Score at Weeks 12 and 16 | Change at Week 16 | 0.8 units on a scale | Standard Error 0.17 |
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline AQLQ as a covariate.p-value: 0.443695% CI: [-0.62, 0.27]Mixed Models Analysis
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline AQLQ as a covariate.p-value: 0.59795% CI: [-0.56, 0.32]Mixed Models Analysis
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline AQLQ as a covariate.p-value: 0.376995% CI: [-0.68, 0.26]Mixed Models Analysis
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline AQLQ as a covariate.p-value: 0.459595% CI: [-0.64, 0.29]Mixed Models Analysis
Secondary
Change From Baseline in the Weekly Average of Daily Morning Trough (Pre-Rescue Bronchodilator) FEV1 Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16
FEV1 was the volume of air exhaled in the first second of a forced expiration as measured by a handheld device. The post-baseline analysis window for over 12 weeks was from the first day of study drug up to Day 84. The post-baseline analysis window for over 16 weeks was from the first day of study drug up to Day 112. The daily average of the efficacy data with each weekly analysis window was calculated based on non-missing e-diary as follow: Summation of FEV1 during an analysis window/Number of days with nonmissing data in the analysis window. LS mean and SE was calculated using an MMRM.
Time frame: Baseline, up to Week 12, up to Week 16
Population: The mITT analysis set included all randomized participants who received at least a partial dose of study drug.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in the Weekly Average of Daily Morning Trough (Pre-Rescue Bronchodilator) FEV1 Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change over 12 weeks | 0.007 liters | Standard Error 0.0373 |
| Placebo | Change From Baseline in the Weekly Average of Daily Morning Trough (Pre-Rescue Bronchodilator) FEV1 Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change over 16 weeks | 0.009 liters | Standard Error 0.0378 |
| TEV-53275 Dose A | Change From Baseline in the Weekly Average of Daily Morning Trough (Pre-Rescue Bronchodilator) FEV1 Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change over 12 weeks | 0.034 liters | Standard Error 0.0365 |
| TEV-53275 Dose A | Change From Baseline in the Weekly Average of Daily Morning Trough (Pre-Rescue Bronchodilator) FEV1 Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change over 16 weeks | 0.036 liters | Standard Error 0.0369 |
| TEV-53275 Dose B | Change From Baseline in the Weekly Average of Daily Morning Trough (Pre-Rescue Bronchodilator) FEV1 Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change over 12 weeks | 0.034 liters | Standard Error 0.0362 |
| TEV-53275 Dose B | Change From Baseline in the Weekly Average of Daily Morning Trough (Pre-Rescue Bronchodilator) FEV1 Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change over 16 weeks | 0.032 liters | Standard Error 0.0367 |
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline FEV1 as a covariate.p-value: 0.600195% CI: [-0.0733, 0.1261]Mixed Models Analysis
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline FEV1 as a covariate.p-value: 0.592295% CI: [-0.0732, 0.1276]Mixed Models Analysis
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline FEV1 as a covariate.p-value: 0.601795% CI: [-0.0744, 0.1277]Mixed Models Analysis
Comparison: Analysis was performed using an MMRM with treatment group, week, randomization factors, and treatment group by week interaction as fixed effects, and baseline FEV1 as a covariate.p-value: 0.666495% CI: [-0.0796, 0.1239]Mixed Models Analysis
Secondary
Change From Baseline in Weekly Average of Rescue Medication Use Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16
The number of times asthma rescue medication (number of inhalations/puffs) was used was assessed (for example, by reviewing the electronic diary or if required due to missing data in the diary, by site tracking of the inhalation counter on the inhaler). Rescue medication included albuterol sulfate inhalation powder (albuterol eMDPI) or equivalent albuterol/salbutamol. The post-baseline analysis window for over 12 weeks was from the first day of study drug up to Day 84. The post-baseline analysis window for over 16 weeks was from the first day of study drug up to Day 112. The daily average of the efficacy data with each weekly analysis window was calculated based on non-missing e-diary as follow: Summation of rescue medication uses during an analysis window/Number of days with nonmissing data in the analysis window. LS mean and SE were calculated using Wilcoxon rank-sum test stratified on randomization stratification factors.
Time frame: Baseline, up to Week 12, up to Week 16
Population: The mITT analysis set included all randomized participants who received at least a partial dose of study drug.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Weekly Average of Rescue Medication Use Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change in weekly average rescue medication use over 12 weeks | -3.7 number of inhalations/week | Standard Deviation 9.21 |
| Placebo | Change From Baseline in Weekly Average of Rescue Medication Use Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change in weekly average rescue medication use over 16 weeks | -4.2 number of inhalations/week | Standard Deviation 9.3 |
| TEV-53275 Dose A | Change From Baseline in Weekly Average of Rescue Medication Use Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change in weekly average rescue medication use over 12 weeks | -3.4 number of inhalations/week | Standard Deviation 5.86 |
| TEV-53275 Dose A | Change From Baseline in Weekly Average of Rescue Medication Use Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change in weekly average rescue medication use over 16 weeks | -3.5 number of inhalations/week | Standard Deviation 5.81 |
| TEV-53275 Dose B | Change From Baseline in Weekly Average of Rescue Medication Use Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change in weekly average rescue medication use over 12 weeks | -2.9 number of inhalations/week | Standard Deviation 8.55 |
| TEV-53275 Dose B | Change From Baseline in Weekly Average of Rescue Medication Use Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change in weekly average rescue medication use over 16 weeks | -3.0 number of inhalations/week | Standard Deviation 8.66 |
Comparison: Analysis was performed using Wilcoxon rank-sum test stratified on randomization stratification factors.p-value: 0.726195% CI: [-2.33, 3.31]Wilcoxon (Mann-Whitney)
Comparison: Analysis was performed using Wilcoxon rank-sum test stratified on randomization stratification factors.p-value: 0.76595% CI: [-3.56, 3.32]Wilcoxon (Mann-Whitney)
Comparison: Analysis was performed using Wilcoxon rank-sum test stratified on randomization stratification factors.p-value: 0.794295% CI: [-2.44, 3.04]Wilcoxon (Mann-Whitney)
Comparison: Analysis was performed using Wilcoxon rank-sum test stratified on randomization stratification factors.p-value: 0.614795% CI: [-3.81, 2.55]Wilcoxon (Mann-Whitney)
Secondary
Change From Baseline in Weekly Percentage of Asthma Control Days (No Symptoms and No Rescue Medication Use) Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16
An asthma control day was defined as a day on which the participant used 0 puffs of inhaled short-acting β-adrenergic agonist (SABA), had no night-time awakenings, and experienced no asthma exacerbations. The post-baseline analysis window for over 12 weeks was from the first day of study drug up to Day 84. The post-baseline analysis window for over 16 weeks was from the first day of study drug up to Day 112. Percentage of asthma control days in each analysis window was calculated as follow: Summation of asthma control days in an analysis window/Number of days with nonmissing data in the analysis window \* 100.
Time frame: Baseline, up to Week 12, up to Week 16
Population: The mITT analysis set included all randomized participants who received at least a partial dose of study drug.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Weekly Percentage of Asthma Control Days (No Symptoms and No Rescue Medication Use) Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change in weekly percentage of asthma control days over 12 weeks | 23.21 percentage of days/week | Standard Deviation 36.645 |
| Placebo | Change From Baseline in Weekly Percentage of Asthma Control Days (No Symptoms and No Rescue Medication Use) Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change in weekly percentage of asthma control days over 16 weeks | 24.28 percentage of days/week | Standard Deviation 36.557 |
| TEV-53275 Dose A | Change From Baseline in Weekly Percentage of Asthma Control Days (No Symptoms and No Rescue Medication Use) Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change in weekly percentage of asthma control days over 12 weeks | 21.51 percentage of days/week | Standard Deviation 23.907 |
| TEV-53275 Dose A | Change From Baseline in Weekly Percentage of Asthma Control Days (No Symptoms and No Rescue Medication Use) Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change in weekly percentage of asthma control days over 16 weeks | 23.23 percentage of days/week | Standard Deviation 25.585 |
| TEV-53275 Dose B | Change From Baseline in Weekly Percentage of Asthma Control Days (No Symptoms and No Rescue Medication Use) Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change in weekly percentage of asthma control days over 12 weeks | 12.71 percentage of days/week | Standard Deviation 27.024 |
| TEV-53275 Dose B | Change From Baseline in Weekly Percentage of Asthma Control Days (No Symptoms and No Rescue Medication Use) Over 12 Weeks From Week 1 Through 12 and Over 16 Weeks From Week 1 Through 16 | Change in weekly percentage of asthma control days over 16 weeks | 13.57 percentage of days/week | Standard Deviation 28.148 |
Secondary
Number of Participants Developing Antidrug Antibodies (ADAs) Throughout the Study
A participant was classified as having a treatment-emergent ADA response if either of the following were true: - The participant had a positive sample at any of the postdose time points, but not at the predose (baseline) time point; - The participant had a positive sample at predose (baseline) and 1 or more postdose time points, but the titer of a postdose sample(s) was increased by at least 4-fold when comparing it to that of the predose sample.
Time frame: Baseline up to Week 30
Population: The ADA analysis set (for anti-TEV-53275 antibodies) included those participants treated with TEV-53275 in the safety analysis set. In this set, data were summarized based upon the treatment actually received regardless of the assigned treatment. One participant was randomized to TEV-53275 Dose B but received TEV-53275 Dose A. Therefore, the participant was included in the TEV-53275 Dose A arm for the ADA Analysis Set.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants Developing Antidrug Antibodies (ADAs) Throughout the Study | 1 Participants |
| TEV-53275 Dose A | Number of Participants Developing Antidrug Antibodies (ADAs) Throughout the Study | 0 Participants |
Secondary
Number of Participants Who Achieved Clinic-based FEV1 ≥80% Predicted at Weeks 12 and 16
The percent of predicted FEV1 (the volume of air exhaled in the first second of a forced expiration) was measured by handheld device.
Time frame: Weeks 12 and 16
Population: The mITT analysis set included all randomized participants who received at least a partial dose of study drug. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed = participants evaluable at specified timepoint.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo | Number of Participants Who Achieved Clinic-based FEV1 ≥80% Predicted at Weeks 12 and 16 | Week 12 | 7 Participants |
| Placebo | Number of Participants Who Achieved Clinic-based FEV1 ≥80% Predicted at Weeks 12 and 16 | Week 16 | 6 Participants |
| TEV-53275 Dose A | Number of Participants Who Achieved Clinic-based FEV1 ≥80% Predicted at Weeks 12 and 16 | Week 12 | 7 Participants |
| TEV-53275 Dose A | Number of Participants Who Achieved Clinic-based FEV1 ≥80% Predicted at Weeks 12 and 16 | Week 16 | 4 Participants |
| TEV-53275 Dose B | Number of Participants Who Achieved Clinic-based FEV1 ≥80% Predicted at Weeks 12 and 16 | Week 12 | 8 Participants |
| TEV-53275 Dose B | Number of Participants Who Achieved Clinic-based FEV1 ≥80% Predicted at Weeks 12 and 16 | Week 16 | 5 Participants |
Secondary
Number of Participants Who Achieved FEV1:FVC Ratio ≥0.80 at Weeks 12 and 16
FEV1 was the volume of air exhaled in the first second of a forced expiration. FVC is the volume of air that can be forcibly blown out after full inspiration.
Time frame: Weeks 12 and 16
Population: The mITT analysis set included all randomized participants who received at least a partial dose of study drug. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed = participants evaluable at specified timepoint.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo | Number of Participants Who Achieved FEV1:FVC Ratio ≥0.80 at Weeks 12 and 16 | Week 16 | 0 Participants |
| Placebo | Number of Participants Who Achieved FEV1:FVC Ratio ≥0.80 at Weeks 12 and 16 | Week 12 | 0 Participants |
| TEV-53275 Dose A | Number of Participants Who Achieved FEV1:FVC Ratio ≥0.80 at Weeks 12 and 16 | Week 12 | 0 Participants |
| TEV-53275 Dose A | Number of Participants Who Achieved FEV1:FVC Ratio ≥0.80 at Weeks 12 and 16 | Week 16 | 0 Participants |
| TEV-53275 Dose B | Number of Participants Who Achieved FEV1:FVC Ratio ≥0.80 at Weeks 12 and 16 | Week 12 | 0 Participants |
| TEV-53275 Dose B | Number of Participants Who Achieved FEV1:FVC Ratio ≥0.80 at Weeks 12 and 16 | Week 16 | 2 Participants |
Secondary
Number of Participants Who Achieved Forced Expiratory Flow at 25% to 75% of Forced Expiratory Volume (FVC) (FEF25-75) ≥70% Predicted at Weeks 12 and 16
The FVC is the volume of air that can be forcibly blown out after full inspiration. FVC results in this study were presented as the forced expiratory flow at 25% to 75% of FVC.
Time frame: Weeks 12 and 16
Population: The mITT analysis set included all randomized participants who received at least a partial dose of study drug. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed = participants evaluable at specified timepoint.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo | Number of Participants Who Achieved Forced Expiratory Flow at 25% to 75% of Forced Expiratory Volume (FVC) (FEF25-75) ≥70% Predicted at Weeks 12 and 16 | Week 12 | 2 Participants |
| Placebo | Number of Participants Who Achieved Forced Expiratory Flow at 25% to 75% of Forced Expiratory Volume (FVC) (FEF25-75) ≥70% Predicted at Weeks 12 and 16 | Week 16 | 2 Participants |
| TEV-53275 Dose A | Number of Participants Who Achieved Forced Expiratory Flow at 25% to 75% of Forced Expiratory Volume (FVC) (FEF25-75) ≥70% Predicted at Weeks 12 and 16 | Week 12 | 3 Participants |
| TEV-53275 Dose A | Number of Participants Who Achieved Forced Expiratory Flow at 25% to 75% of Forced Expiratory Volume (FVC) (FEF25-75) ≥70% Predicted at Weeks 12 and 16 | Week 16 | 2 Participants |
| TEV-53275 Dose B | Number of Participants Who Achieved Forced Expiratory Flow at 25% to 75% of Forced Expiratory Volume (FVC) (FEF25-75) ≥70% Predicted at Weeks 12 and 16 | Week 16 | 2 Participants |
| TEV-53275 Dose B | Number of Participants Who Achieved Forced Expiratory Flow at 25% to 75% of Forced Expiratory Volume (FVC) (FEF25-75) ≥70% Predicted at Weeks 12 and 16 | Week 12 | 1 Participants |
Secondary
Number of Participants Who Did Not Complete the Study Due to AEs
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Number of participants who did not complete the study due to AEs were reported.
Time frame: Baseline up to Week 30
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug. In this set, data were summarized based upon the treatment actually received regardless of the assigned treatment. One participant was randomized to TEV-53275 Dose B but received TEV-53275 Dose A. Therefore, the participant was included in the TEV-53275 Dose A arm for the Safety Analysis Set.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants Who Did Not Complete the Study Due to AEs | 0 Participants |
| TEV-53275 Dose A | Number of Participants Who Did Not Complete the Study Due to AEs | 0 Participants |
| TEV-53275 Dose B | Number of Participants Who Did Not Complete the Study Due to AEs | 0 Participants |
Secondary
Number of Participants Who Received at Least 1 Concomitant Asthma Medication
Concomitant asthma medications included Antihistamines for systemic use (Cetirizine); Corticosteroids for systemic use (Prednisone, Methylprednisolone); and Drugs for obstructive airway diseases (Salbutamol, Fluticasone etc.).
Time frame: Baseline up to Week 30
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug. In this set, data were summarized based upon the treatment actually received regardless of the assigned treatment. One participant was randomized to TEV-53275 Dose B but received TEV-53275 Dose A. Therefore, the participant was included in the TEV-53275 Dose A arm for the Safety Analysis Set.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants Who Received at Least 1 Concomitant Asthma Medication | 31 Participants |
| TEV-53275 Dose A | Number of Participants Who Received at Least 1 Concomitant Asthma Medication | 34 Participants |
| TEV-53275 Dose B | Number of Participants Who Received at Least 1 Concomitant Asthma Medication | 31 Participants |
Secondary
Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Hematology Value
Potentially clinically significant hematological abnormalities included: White blood cells (WBCs) count ≤3.0 \*10\^9 cells/L or ≥20 \* 10\^9 cells/L; Hemoglobin ≤95 grams (g)/L in females and ≤115 g/L in males; Hematocrit \<0.32 L/L in females and \<0.37 L/L in males; Platelet count ≤75 \* 10\^9 cells/L or ≥700 \* 10\^9 cells/L; and Absolute neutrophil count (ANC) ≤1 \* 10\^9 cells/L.
Time frame: Baseline up to Week 30
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug. In this set, data were summarized based upon the treatment actually received regardless of the assigned treatment. One participant was randomized to TEV-53275 Dose B but received TEV-53275 Dose A. Therefore, the participant was included in the TEV-53275 Dose A arm for the Safety Analysis Set.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Hematology Value | 1 Participants |
| TEV-53275 Dose A | Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Hematology Value | 2 Participants |
| TEV-53275 Dose B | Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Hematology Value | 0 Participants |
Secondary
Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Serum Chemistry Value
Potentially clinically significant serum chemistry abnormalities included: Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase, Gamma-glutamyl transpeptidase (GGT), Lactate dehydrogenase (LDH), and Creatinine phosphokinase each ≥3 \* upper limit of normal (ULN); Blood urea nitrogen ≥10.71 millimoles (mmol)/liter (L); Creatinine ≥177 micromoles (μmol)/L; and Bilirubin (total) ≥34.2 μmol /L.
Time frame: Baseline up to Week 30
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug. In this set, data were summarized based upon the treatment actually received regardless of the assigned treatment. One participant was randomized to TEV-53275 Dose B but received TEV-53275 Dose A. Therefore, the participant was included in the TEV-53275 Dose A arm for the Safety Analysis Set.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Serum Chemistry Value | 2 Participants |
| TEV-53275 Dose A | Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Serum Chemistry Value | 3 Participants |
| TEV-53275 Dose B | Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Serum Chemistry Value | 2 Participants |
Secondary
Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Vital Signs Value
Potentially clinically significant vital signs abnormalities included: Systolic blood pressure (BP): ≤90 millimeters of mercury (mmHg) and decrease from baseline of 20 mm Hg or ≥180 mm Hg and increase from baseline of ≥20 mm Hg; Diastolic BP: ≥105 mmHg and increase from baseline of ≥15 mmHg or ≤50 mmHg and decrease from baseline of ≥15 mmHg; Pulse ≥120 beats per minute (bpm) and increase from baseline of ≥15 bpm or ≤50 bpm and decrease from baseline of ≥15 bpm; Temperature ≥38.3 degrees celsius (ºC) and change from baseline of ≥1.1 ºC; Respiratory rate \>24 breaths/min and increase from baseline of ≥10 breaths/min.
Time frame: Baseline up to Week 30
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug. In this set, data were summarized based upon the treatment actually received regardless of the assigned treatment. One participant was randomized to TEV-53275 Dose B but received TEV-53275 Dose A. Therefore, the participant was included in the TEV-53275 Dose A arm for the Safety Analysis Set.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Vital Signs Value | 1 Participants |
| TEV-53275 Dose A | Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Vital Signs Value | 0 Participants |
| TEV-53275 Dose B | Number of Participants With at Least 1 Potentially Clinically Significant Abnormal Vital Signs Value | 0 Participants |
Secondary
Number of Participants With at Least 1 Potentially Clinically Significant Urinalysis Abnormalities
Potentially clinically significant urinalysis abnormalities included: ≥2 unit increase from baseline in urine hemoglobin, ketones, glucose, and total protein.
Time frame: Baseline up to Week 30
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug. In this set, data were summarized based upon the treatment actually received regardless of the assigned treatment. One participant was randomized to TEV-53275 Dose B but received TEV-53275 Dose A. Therefore, the participant was included in the TEV-53275 Dose A arm for the Safety Analysis Set. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With at Least 1 Potentially Clinically Significant Urinalysis Abnormalities | 4 Participants |
| TEV-53275 Dose A | Number of Participants With at Least 1 Potentially Clinically Significant Urinalysis Abnormalities | 3 Participants |
| TEV-53275 Dose B | Number of Participants With at Least 1 Potentially Clinically Significant Urinalysis Abnormalities | 3 Participants |
Secondary
Number of Participants With Injection Site Reactions
Injection site reactions included erythema, ecchymosis, induration, tenderness, warmth, and swelling. Number of participants with erythema, ecchymosis, and induration were reported in following categories: Absent; 5 millimeters (mm) to ≤50 mm (mild); \>50 mm to ≤100 mm (moderate); and \>100 mm (severe). Number of participants with tenderness, warmth, and swelling were reported in following categories: Absent; mild; moderate; and severe.
Time frame: Baseline up to Week 30
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug. In this set, data were summarized based upon the treatment actually received regardless of the assigned treatment. One participant was randomized to TEV-53275 Dose B but received TEV-53275 Dose A. Therefore, the participant was included in the TEV-53275 Dose A arm for the Safety Analysis Set.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Placebo | Number of Participants With Injection Site Reactions | Ecchymosis | Mild | 0 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Erythema | Absent | 27 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Erythema | Mild | 4 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Erythema | Moderate | 0 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Erythema | Severe | 0 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Ecchymosis | Absent | 31 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Ecchymosis | Moderate | 0 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Ecchymosis | Severe | 0 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Induration | Absent | 31 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Induration | Mild | 0 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Induration | Moderate | 0 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Induration | Severe | 0 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Tenderness | Absent | 26 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Tenderness | Mild | 5 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Tenderness | Moderate | 0 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Tenderness | Severe | 0 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Warmth | Absent | 31 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Warmth | Mild | 0 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Warmth | Moderate | 0 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Warmth | Severe | 0 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Swelling | Absent | 29 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Swelling | Mild | 2 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Swelling | Moderate | 0 Participants |
| Placebo | Number of Participants With Injection Site Reactions | Swelling | Severe | 0 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Swelling | Mild | 3 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Ecchymosis | Mild | 1 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Warmth | Absent | 30 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Erythema | Absent | 29 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Induration | Moderate | 0 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Tenderness | Absent | 32 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Erythema | Mild | 4 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Warmth | Severe | 0 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Swelling | Absent | 30 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Erythema | Moderate | 1 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Tenderness | Mild | 1 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Warmth | Mild | 4 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Erythema | Severe | 0 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Induration | Mild | 2 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Tenderness | Moderate | 1 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Ecchymosis | Absent | 33 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Induration | Absent | 32 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Induration | Severe | 0 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Swelling | Severe | 0 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Ecchymosis | Moderate | 0 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Tenderness | Severe | 0 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Warmth | Moderate | 0 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Ecchymosis | Severe | 0 Participants |
| TEV-53275 Dose A | Number of Participants With Injection Site Reactions | Swelling | Moderate | 1 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Ecchymosis | Severe | 0 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Induration | Absent | 29 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Induration | Mild | 2 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Induration | Moderate | 0 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Warmth | Severe | 0 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Tenderness | Mild | 2 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Induration | Severe | 0 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Swelling | Moderate | 0 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Tenderness | Absent | 27 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Swelling | Absent | 28 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Tenderness | Moderate | 2 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Swelling | Severe | 0 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Tenderness | Severe | 0 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Erythema | Absent | 21 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Warmth | Absent | 30 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Erythema | Mild | 8 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Swelling | Mild | 3 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Erythema | Moderate | 2 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Erythema | Severe | 0 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Warmth | Mild | 1 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Ecchymosis | Absent | 30 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Ecchymosis | Mild | 1 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Ecchymosis | Moderate | 0 Participants |
| TEV-53275 Dose B | Number of Participants With Injection Site Reactions | Warmth | Moderate | 0 Participants |
Secondary
Number of Participants With Potentially Clinically Significant Abnormal Electrocardiogram Values
Potentially clinically significant electrocardiogram abnormalities including any one of the following values: QTc interval \>450 milliseconds (msec) and QTc interval increases from baseline \>30 msec, QTc interval \>450 msec and QTc interval increases from baseline \>60 msec, QTc interval \>500 msec and QTc interval increases from baseline \>30 msec, QTc interval \>500 msec and QTc interval increases from baseline \>60 msec; QRS duration \>110 msec and a 25% increase from baseline; and PR interval \>200 msec and a 25% increase from baseline.
Time frame: Baseline up to Week 30
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug. In this set, data were summarized based upon the treatment actually received regardless of the assigned treatment. One participant was randomized to TEV-53275 Dose B but received TEV-53275 Dose A. Therefore, the participant was included in the TEV-53275 Dose A arm for the Safety Analysis Set.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With Potentially Clinically Significant Abnormal Electrocardiogram Values | 0 Participants |
| TEV-53275 Dose A | Number of Participants With Potentially Clinically Significant Abnormal Electrocardiogram Values | 1 Participants |
| TEV-53275 Dose B | Number of Participants With Potentially Clinically Significant Abnormal Electrocardiogram Values | 0 Participants |
Secondary
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse events (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. TEAEs were defined as AEs that occurred after the first dose of study drug was administered through the end of the study. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Baseline up to Week 30
Population: Safety analysis set included all randomized participants who received at least 1 dose of study drug. In this set, data were summarized based upon the treatment actually received regardless of the assigned treatment. One participant was randomized to TEV-53275 Dose B but received TEV-53275 Dose A. Therefore, the participant was included in the TEV-53275 Dose A arm for the Safety Analysis Set.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 11 Participants |
| TEV-53275 Dose A | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 22 Participants |
| TEV-53275 Dose B | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 14 Participants |
Secondary
Number of Participants With Well-controlled Asthma Status (Yes Versus No) at Weeks 12 and 16
The weekly asthma control status (Yes or No) is the derived asthma control composite score based on the following criteria: 1\. Two or more of the following criteria were fulfilled: * ≤2 days with a daily asthma symptom score \>1; - ≤2 days of albuterol/salbutamol used as rescue medication up to a maximum of 4 occasions per week (multiple occasions per day are counted as separate occasions); - morning FEV1 ≥80% predicted for each day (by handheld device) and 2. Both of the following criteria were fulfilled: * no night-time awakenings due to asthma; - no use of asthma maintenance medications. The asthma control status in each weekly analysis window was Yes if the conditions 1 and 2 above were met, No otherwise.
Time frame: Weeks 12 and 16
Population: The mITT analysis set included all randomized participants who received at least a partial dose of study drug. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure. 'Number analyzed = participants evaluable at specified timepoint.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Placebo | Number of Participants With Well-controlled Asthma Status (Yes Versus No) at Weeks 12 and 16 | Well-controlled asthma status at Week 12 | Yes | 6 Participants |
| Placebo | Number of Participants With Well-controlled Asthma Status (Yes Versus No) at Weeks 12 and 16 | Well-controlled asthma status at Week 12 | No | 17 Participants |
| Placebo | Number of Participants With Well-controlled Asthma Status (Yes Versus No) at Weeks 12 and 16 | Well-controlled asthma status at Week 16 | Yes | 6 Participants |
| Placebo | Number of Participants With Well-controlled Asthma Status (Yes Versus No) at Weeks 12 and 16 | Well-controlled asthma status at Week 16 | No | 17 Participants |
| TEV-53275 Dose A | Number of Participants With Well-controlled Asthma Status (Yes Versus No) at Weeks 12 and 16 | Well-controlled asthma status at Week 16 | No | 12 Participants |
| TEV-53275 Dose A | Number of Participants With Well-controlled Asthma Status (Yes Versus No) at Weeks 12 and 16 | Well-controlled asthma status at Week 12 | Yes | 11 Participants |
| TEV-53275 Dose A | Number of Participants With Well-controlled Asthma Status (Yes Versus No) at Weeks 12 and 16 | Well-controlled asthma status at Week 16 | Yes | 12 Participants |
| TEV-53275 Dose A | Number of Participants With Well-controlled Asthma Status (Yes Versus No) at Weeks 12 and 16 | Well-controlled asthma status at Week 12 | No | 15 Participants |
| TEV-53275 Dose B | Number of Participants With Well-controlled Asthma Status (Yes Versus No) at Weeks 12 and 16 | Well-controlled asthma status at Week 16 | No | 20 Participants |
| TEV-53275 Dose B | Number of Participants With Well-controlled Asthma Status (Yes Versus No) at Weeks 12 and 16 | Well-controlled asthma status at Week 12 | No | 21 Participants |
| TEV-53275 Dose B | Number of Participants With Well-controlled Asthma Status (Yes Versus No) at Weeks 12 and 16 | Well-controlled asthma status at Week 16 | Yes | 6 Participants |
| TEV-53275 Dose B | Number of Participants With Well-controlled Asthma Status (Yes Versus No) at Weeks 12 and 16 | Well-controlled asthma status at Week 12 | Yes | 6 Participants |
Secondary
Time to First Clinical Asthma Exacerbation (CAE)
The time (days) to the first CAE was the interval from the randomization to the occurrence of the first CAE. A CAE was defined as worsening asthma requiring treatment with a systemic corticosteroid for at least 3 days, emergency room visit resulting in systemic corticosteroid treatment, or hospitalization due to asthma. Worsening asthma included new or increased symptoms or signs that either worried the participant or were related to an asthma-specific alert (if available through the electronic diary/handheld spirometer) and required the addition of maintenance medications (other than systemic corticosteroids) to control the participant's asthma symptoms based on the investigator's judgment.
Time frame: Baseline up to Week 16
Population: The mITT analysis set included all randomized participants who received at least a partial dose of study drug. Here, 'Overall number of participants analyzed' = participants evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Time to First Clinical Asthma Exacerbation (CAE) | 54.5 days | Standard Deviation 36.06 |
| TEV-53275 Dose A | Time to First Clinical Asthma Exacerbation (CAE) | 77.0 days | Standard Deviation 47.82 |
| TEV-53275 Dose B | Time to First Clinical Asthma Exacerbation (CAE) | 87.0 days | Standard Deviation 36.77 |